Fundraising FoxPrevisedx
1 known investors
Find your way into Previsedx
Sign up to see every warm intro you have to Previsedx
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Previsedx team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Esopredict is a methylation-based risk-stratification test that quantifies DNA methylation of four genes (p16, RUNX3, HPP1, FBN1) combined with patient age to predict a patient's 5-year risk of progressing from Barrett's esophagus to high-grade dysplasia or esophageal adenocarcinoma. Offered by Castle as a companion to its TissueCypher test, it produces a risk score and risk level to help clinicians manage patients with non-dysplastic, indefinite, or low-grade Barrett's esophagus.
Investors · 1
Frequently asked questions
- What does Previsedx do?
- Esopredict is a methylation-based risk-stratification test that quantifies DNA methylation of four genes (p16, RUNX3, HPP1, FBN1) combined with patient age to predict a patient's 5-year risk of progressing from Barrett's esophagus to high-grade dysplasia or esophageal adenocarcinoma. Offered by Castle as a companion to its TissueCypher test, it produces a risk score and risk level to help clinicians manage patients with non-dysplastic, indefinite, or low-grade Barrett's esophagus.
- Who are Previsedx's investors?
- Previsedx's investors include Riptide Ventures.